GSK (LON:GSK) Stock: Insider Julie Brown Purchases 7 Shares

Key Points

• Insider purchase: GSK director Julie Brown bought 7 shares at GBX 1,765 each, totaling £123.55. She also purchased 7 shares in September.
• Stock performance: GSK shares rose 1.1% to GBX 1,771, but remained below their 50-day and 200-day moving averages and well below the 1-year high of GBX 2,282.
• Analyst outlook: GSK has a consensus “Hold” rating and an average price target of GBX 2,064.38, with ratings ranging from Buy to Sell.

GSK plc (LON:GSK - Get Free Report) insider Julie Brown purchased 7 shares of GSK stock in a transaction dated Friday, October 9th. The shares were acquired at an average cost of GBX 1,765 per share, for a total transaction of £123.55.

Julie Brown also recently made the following trade(s):

• On Wednesday, September 9th, Julie Brown acquired 7 shares of GSK stock. The stock was acquired at an average cost of GBX 1,803 per share, with a total value of £126.21.

GSK Stock Up 1.1%

Shares of GSK stock traded up GBX 19 during trading on Monday, reaching GBX 1,771. The company's stock had a trading volume of 3,152,165 shares, compared to its average volume of 12,615,232. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73. The company has a market capitalization of £70.96 billion, a price-to-earnings ratio of 15.03, a P/E/G ratio of 1.24 and a beta of 0.29. The stock's 50-day moving average price is GBX 1,858.40 and its 200 day moving average price is GBX 1,933.21. GSK plc has a 1-year low of GBX 1,592 and a 1-year high of GBX 2,282.

GSK (LON:GSK - Get Free Report) last announced its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. On average, research analysts anticipate that GSK plc will post 175.98 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Jefferies Financial Group reissued a "buy" rating and set a GBX 2,500 target price on shares of GSK in a research note on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a GBX 2,000 price objective on shares of GSK in a research note on Tuesday, September 29th. Berenberg Bank boosted their price objective on GSK from GBX 2,000 to GBX 2,200 and gave the stock a "hold" rating in a research report on Tuesday, September 15th. Finally, Royal Bank Of Canada reissued a "sector perform" rating and set a GBX 1,975 price objective on shares of GSK in a research report on Tuesday, September 8th. Two equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, GSK has a consensus rating of "Hold" and a consensus price target of GBX 2,064.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.